FDA approved the 50th biosimilar and released the new Biosimilars Action Plan (BAP). Since FDA’s biosimilars program started, the agency has contributed to the growth of biosimilar adoption and the increasing availability of therapeutic options for patients who face increasing costs and restrictions to access much needed medications. FDA has approved biosimilars to treat a wide range of conditions such as diabetes, skin conditions, bowel disorders, and more. These treatment options can give pati